CONMED Corporation (NASDAQ:CNMD)‘s stock had its “hold” rating reissued by equities research analysts at KeyCorp in a research report issued to clients and investors on Friday. KeyCorp also issued estimates for CONMED Corporation’s FY2017 earnings at $1.86 EPS, FY2018 earnings at $2.06 EPS and FY2019 earnings at $2.32 EPS.

A number of other equities analysts have also commented on the company. Needham & Company LLC lifted their price objective on CONMED Corporation from $54.00 to $57.00 and gave the stock a “buy” rating in a research note on Thursday, July 27th. Piper Jaffray Companies reaffirmed a “hold” rating and issued a $46.00 price objective on shares of CONMED Corporation in a research note on Friday. BidaskClub raised CONMED Corporation from a “strong sell” rating to a “sell” rating in a research note on Monday, August 14th. TheStreet raised CONMED Corporation from a “c+” rating to a “b-” rating in a research note on Thursday, August 3rd. Finally, Zacks Investment Research lowered CONMED Corporation from a “hold” rating to a “sell” rating in a research note on Friday, July 28th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and one has given a buy rating to the company. CONMED Corporation presently has a consensus rating of “Hold” and a consensus target price of $50.33.

Shares of CONMED Corporation (CNMD) traded up $0.16 during mid-day trading on Friday, hitting $53.37. The stock had a trading volume of 118,854 shares, compared to its average volume of 88,131. The company has a quick ratio of 1.57, a current ratio of 2.62 and a debt-to-equity ratio of 0.83. CONMED Corporation has a 12-month low of $39.09 and a 12-month high of $54.47. The firm has a market capitalization of $1.49 billion, a price-to-earnings ratio of 30.41, a price-to-earnings-growth ratio of 3.35 and a beta of 0.66.

CONMED Corporation (NASDAQ:CNMD) last announced its quarterly earnings results on Thursday, November 2nd. The medical technology company reported $0.42 EPS for the quarter, beating the Zacks’ consensus estimate of $0.41 by $0.01. CONMED Corporation had a return on equity of 8.43% and a net margin of 1.99%. The firm had revenue of $190.10 million for the quarter, compared to analyst estimates of $187.13 million. During the same period last year, the firm posted $0.41 earnings per share. The business’s revenue for the quarter was up 2.9% on a year-over-year basis. analysts forecast that CONMED Corporation will post 1.87 EPS for the current year.

WARNING: This piece of content was reported by American Banking News and is owned by of American Banking News. If you are reading this piece of content on another website, it was stolen and reposted in violation of United States and international copyright & trademark laws. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2017/11/04/conmed-corporation-cnmd-given-hold-rating-at-keycorp.html.

In related news, Director Jo Ann Golden sold 3,000 shares of CONMED Corporation stock in a transaction that occurred on Monday, August 14th. The stock was sold at an average price of $50.00, for a total value of $150,000.00. Following the transaction, the director now directly owns 19,782 shares of the company’s stock, valued at $989,100. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 2.62% of the stock is owned by insiders.

A number of hedge funds have recently modified their holdings of CNMD. BlackRock Inc. increased its holdings in CONMED Corporation by 46,036.5% in the first quarter. BlackRock Inc. now owns 3,153,427 shares of the medical technology company’s stock worth $140,043,000 after purchasing an additional 3,146,592 shares in the last quarter. AHL Partners LLP increased its holdings in CONMED Corporation by 2,792.2% in the second quarter. AHL Partners LLP now owns 158,090 shares of the medical technology company’s stock worth $8,053,000 after purchasing an additional 152,624 shares in the last quarter. Heartland Advisors Inc. increased its holdings in CONMED Corporation by 315.7% in the second quarter. Heartland Advisors Inc. now owns 165,992 shares of the medical technology company’s stock worth $8,456,000 after purchasing an additional 126,062 shares in the last quarter. Victory Capital Management Inc. increased its holdings in CONMED Corporation by 5.4% in the third quarter. Victory Capital Management Inc. now owns 2,180,586 shares of the medical technology company’s stock worth $114,415,000 after purchasing an additional 111,096 shares in the last quarter. Finally, Vanguard Group Inc. increased its holdings in CONMED Corporation by 3.9% in the first quarter. Vanguard Group Inc. now owns 2,268,882 shares of the medical technology company’s stock worth $100,761,000 after purchasing an additional 84,785 shares in the last quarter. Institutional investors and hedge funds own 98.36% of the company’s stock.

About CONMED Corporation

CONMED Corporation is a medical technology company. The Company is engaged in the development, manufacturing and sale on a global basis of surgical devices and related equipment. The Company provides surgical devices and equipment for minimally invasive procedures. The Company’s products are used by surgeons and physicians in a range of specialties, including orthopedics, general surgery, gynecology, neurosurgery and gastroenterology.

Analyst Recommendations for CONMED Corporation (NASDAQ:CNMD)

Receive News & Ratings for CONMED Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CONMED Corporation and related companies with MarketBeat.com's FREE daily email newsletter.